User login
Key clinical point: High serum levels of angiopoietin 2 (Ang2) levels identified patients with hepatocellular carcinoma (HCC) and predicted a shorter time to recurrence after treatment with curative intent.
Major finding: Serum Ang2 levels were significantly higher in patients with HCC vs controls (P less than .001) and patients with chronic liver disease (P less than .001). At the optimal threshold (3.5 ng/mL), sensitivity, specificity, and accuracy were 51%, 84%, and 59.5%, respectively. Higher serum Ang2 levels correlated with significantly shorter recurrence-free survival after ablation therapy, even after controlling for other prognostic factors.
Study details: The researchers reviewed medical charts and used sandwich enzyme-linked immunosorbent assay (ELISA) to measure Ang2 levels in stored serum from 275 patients with HCC, 98 patients with chronic liver disease, and 20 controls.
Disclosures: Partial funding came from the Japan Society for the Promotion of Science and the Program for Basic and Clinical Research on Hepatitis from Japan Agency for Medical Research and Development. The researchers reported having no conflicts of interest.
Source: J Ao et al. J Cancer. 2021 Mar 5. doi: 10.7150/jca.56436
Key clinical point: High serum levels of angiopoietin 2 (Ang2) levels identified patients with hepatocellular carcinoma (HCC) and predicted a shorter time to recurrence after treatment with curative intent.
Major finding: Serum Ang2 levels were significantly higher in patients with HCC vs controls (P less than .001) and patients with chronic liver disease (P less than .001). At the optimal threshold (3.5 ng/mL), sensitivity, specificity, and accuracy were 51%, 84%, and 59.5%, respectively. Higher serum Ang2 levels correlated with significantly shorter recurrence-free survival after ablation therapy, even after controlling for other prognostic factors.
Study details: The researchers reviewed medical charts and used sandwich enzyme-linked immunosorbent assay (ELISA) to measure Ang2 levels in stored serum from 275 patients with HCC, 98 patients with chronic liver disease, and 20 controls.
Disclosures: Partial funding came from the Japan Society for the Promotion of Science and the Program for Basic and Clinical Research on Hepatitis from Japan Agency for Medical Research and Development. The researchers reported having no conflicts of interest.
Source: J Ao et al. J Cancer. 2021 Mar 5. doi: 10.7150/jca.56436
Key clinical point: High serum levels of angiopoietin 2 (Ang2) levels identified patients with hepatocellular carcinoma (HCC) and predicted a shorter time to recurrence after treatment with curative intent.
Major finding: Serum Ang2 levels were significantly higher in patients with HCC vs controls (P less than .001) and patients with chronic liver disease (P less than .001). At the optimal threshold (3.5 ng/mL), sensitivity, specificity, and accuracy were 51%, 84%, and 59.5%, respectively. Higher serum Ang2 levels correlated with significantly shorter recurrence-free survival after ablation therapy, even after controlling for other prognostic factors.
Study details: The researchers reviewed medical charts and used sandwich enzyme-linked immunosorbent assay (ELISA) to measure Ang2 levels in stored serum from 275 patients with HCC, 98 patients with chronic liver disease, and 20 controls.
Disclosures: Partial funding came from the Japan Society for the Promotion of Science and the Program for Basic and Clinical Research on Hepatitis from Japan Agency for Medical Research and Development. The researchers reported having no conflicts of interest.
Source: J Ao et al. J Cancer. 2021 Mar 5. doi: 10.7150/jca.56436